Table 3.
Multivariate analysis of clinical parameters affecting the prognosis of IIIA-N2 NSCLC patients.
| Parameters | All patients (n = 3,445) | No. of patients with <6 positive lymph nodes (n = 2,735) | No. of patients with ≥6 positive lymph nodes (n = 710) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| PORT | |||||||||
| No | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| Yes | 0.931 | 0.830–1.045 | 0.226 | 1.012 | 0.886–1.156 | 0.858 | 0.724 | 0.574–0.914 | 0.007 |
| Age at diagnosis | |||||||||
| <60 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| ≥60 | 1.322 | 1.158–1.510 | <0.001 | 1.303 | 1.114–1.524 | 0.001 | 1.356 | 1.051–1.748 | 0.019 |
| Gender | |||||||||
| Male | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| Female | 0.696 | 0.626–0.775 | <0.001 | 0.667 | 0.589–0.755 | <0.001 | 0.776 | 0.627–0.961 | 0.020 |
| Race | |||||||||
| Black | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| White | 1.091 | 0.907–1.312 | 0.357 | 1.104 | 0.889–1.372 | 0.371 | 1.090 | 0.765–1.553 | 0.632 |
| Other | 0.833 | 0.639–1.085 | 0.175 | 0.757 | 0.551–1.039 | 0.085 | 1.084 | 0.661–1.777 | 0.749 |
| Year of diagnosis | |||||||||
| 2010 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| 2011 | 1.028 | 0.888–1.189 | 0.713 | 1.039 | 0.877–1.232 | 0.657 | 0.971 | 0.725–1.301 | 0.844 |
| 2012 | 1.026 | 0.880–1.196 | 0.745 | 1.066 | 0.891–1.276 | 0.483 | 0.943 | 0.693–1.281 | 0.706 |
| 2013 | 0.964 | 0.810–1.146 | 0.675 | 0.987 | 0.808–1.206 | 0.900 | 0.884 | 0.619–1.264 | 0.500 |
| 2014 | 0.871 | 0.708–1.073 | 0.194 | 0.870 | 0.680–1.111 | 0.264 | 0.846 | 0.572–1.253 | 0.404 |
| 2015 | 0.799 | 0.564–1.132 | 0.207 | 0.819 | 0.538–1.246 | 0.351 | 0.772 | 0.413–1.444 | 0.418 |
| Primary tumor site | |||||||||
| Main bronchus | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| Upper lobe | 1.073 | 0.628–1.833 | 0.797 | 1.232 | 0.608–2.498 | 0.563 | 0.857 | 0.372–1.976 | 0.717 |
| Middle lobe | 1.119 | 0.624–2.006 | 0.705 | 1.280 | 0.600–2.734 | 0.523 | 0.831 | 0.325–2.125 | 0.699 |
| Lower lobe | 1.274 | 0.744–2.181 | 0.377 | 1.461 | 0.719–2.968 | 0.295 | 1.016 | 0.439–2.353 | 0.970 |
| Overlapping lesion | 1.487 | 0.799–2.768 | 0.211 | 1.523 | 0.680–3.411 | 0.306 | 1.663 | 0.609–4.536 | 0.321 |
| Unknown | 0.892 | 0.394–2.020 | 0.784 | 1.926 | 0.737–5.035 | 0.181 | 0.148 | 0.017–1.251 | 0.079 |
| Pathology | |||||||||
| Adenocarcinoma | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| Squamous cell | 1.159 | 1.022–1.316 | 0.022 | 1.194 | 1.035–1.378 | 0.015 | 1.037 | 0.784–1.371 | 0.800 |
| Others | 1.244 | 0.994–1.558 | 0.057 | 1.296 | 1.009–1.664 | 0.043 | 0.999 | 0.587–1.698 | 0.996 |
| Pathological grade | |||||||||
| I | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| II | 0.960 | 0.750–1.228 | 0.745 | 0.950 | 0.717–1.259 | 0.722 | 0.978 | 0.580–1.650 | 0.934 |
| III | 1.159 | 0.906–1.483 | 0.239 | 1.119 | 0.845–1.482 | 0.432 | 1.291 | 0.764–2.183 | 0.341 |
| IV | 1.211 | 0.752–1.950 | 0.432 | 1.323 | 0.763–2.297 | 0.319 | 1.021 | 0.382–2.729 | 0.967 |
| Unknown | 1.029 | 0.749–1.412 | 0.861 | 0.891 | 0.617–1.285 | 0.536 | 1.516 | 0.790–2.906 | 0.211 |
| T | |||||||||
| T1 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| T2 | 1.161 | 1.020–1.322 | 0.024 | 1.210 | 1.044–1.403 | 0.011 | 1.021 | 0.773–1.347 | 0.886 |
| T3 | 1.492 | 1.280–1.738 | <0.001 | 1.531 | 1.284–1.825 | <0.001 | 1.420 | 1.035–1.947 | 0.030 |
| POCT | |||||||||
| No | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| Yes | 0.573 | 0.507–0.648 | <0.001 | 0.573 | 0.498–0.660 | <0.001 | 0.605 | 0.468–0.783 | <0.001 |
| No. of positive lymph nodes | |||||||||
| <6 | 1.00 (Ref) | —— | —— | ||||||
| ≥6 | 1.602 | 1.420–1.807 | <0.001 | —— | —— | —— | —— | —— | —— |
Pathological grade I, well-differentiated; II, moderately differentiated; III, poorly differentiated; IV, undifferentiated, anaplastic.
HR, hazard ratio; Ref, reference; PORT, post operative radiotherapy; POCT, postoperative chemotherapy; NSCLC, non-small cell lung cancer.